JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

  NCT03072927

  Condition:   Lumbar Spinal Stenosis
  Intervention:   Device: MILD
  Sponsor:   Vertos Medical, Inc.
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

  NCT04003389

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

  NCT04003142

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• Blood and Stool Sample Collection in Subjects Participating in Colorectal Cancer Screening: Act Bold

  NCT03821948

  Condition:   Colorectal Cancer
  Intervention:  
  Sponsor:   Exact Sciences Corporation
  Recruiting
• XIENCE 28 USA Study

  NCT03815175

  Conditions:   Bleeding Disorder;   Ischemic Stroke;   Hemorrhagic Stroke;   Hematological Diseases;   Thrombocytopenia;   Coagulation Disorder;   Anemia;   Renal Insufficiency;   Coronary Artery Disease
  Interventions:   Device: XIENCE;   Drug: DAPT (aspirin and/or P2Y12 receptor inhibitor)
  Sponsor:   Abbott Medical Devices
  Recruiting
• A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

  NCT03766581

  Conditions:   Acute Ischemic Stroke;   Transient Ischemic Attack (TIA)
  Interventions:   Drug: BMS-986177;   Other: Placebo;   Drug: Clopidogrel;   Drug: Aspirin
  Sponsors:   Bristol-Myers Squibb;   Janssen, LP
  Recruiting
• Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer

  NCT03633006

  Condition:   Lung Cancer (Diagnosis)
  Intervention:   Other: Blood Sample Collection
  Sponsor:   Exact Sciences Corporation
  Recruiting
• The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

  NCT03551496

  Condition:   Critical Limb Ischemia
  Interventions:   Combination Product: Drug Eluting Stent - Below the Knee;   Device: Standard PTA Control Arm
  Sponsor:   Boston Scientific Corporation
  Recruiting
• A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

  NCT03541174

  Condition:   Resistant Hypertension
  Interventions:   Drug: Aprocitentan 12.5 mg;   Drug: Aprocitentan 25 mg;   Drug: Placebo
  Sponsors:   Idorsia Pharmaceuticals Ltd.;   Janssen Biotech, Inc.
  Recruiting
• Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

  NCT03488693

  Condition:   Breast Cancer
  Interventions:   Radiation: Radiation;   Other: No Radiation
  Sponsors:   Canadian Cancer Trials Group;   Alliance for Clinical Trials in Oncology;   Eastern Cooperative Oncology Group;   NRG Oncology;   Southwest Oncology Group
  Recruiting
• Benefits of µCor in Ambulatory Decompensated Heart Failure

  NCT03476187

  Condition:   Heart Failure
  Intervention:   Device: µCor
  Sponsor:   Zoll Medical Corporation
  Recruiting
• Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

  NCT03281954

  Condition:   Triple Negative Breast Cancer
  Interventions:   Drug: Placebo;   Drug: Atezolizumab
  Sponsors:   NSABP Foundation Inc;   Genentech, Inc.;   Hoffmann-La Roche
  Recruiting
• Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

  NCT03070886

  Conditions:   Stage I Prostate Adenocarcinoma;   Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
  Interventions:   Drug: Bicalutamide;   Drug: Docetaxel;   Radiation: External Beam Radiation Therapy;   Drug: Flutamide;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Drug: Leuprolide Acetate;   Drug: Nilutamide
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

  NCT02997228

  Conditions:   Colorectal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

  NCT02954874

  Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

  NCT02924727

  Condition:   Acute Myocardial Infarction
  Interventions:   Drug: LCZ696 (sacubitril/valsartan);   Drug: Ramipril;   Drug: Placebo of LCZ696;   Drug: Placebo of ramipril;   Drug: Valsartan;   Drug: Placebo of valsartan
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013

  Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
  Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217

  Condition:   Carotid Stenosis
  Interventions:   Procedure: Carotid endarterectomy (CEA);   Device: Carotid Stenting (CAS);   Other: Intensive Medical Management - no CEA;   Other: Intensive Medical Management - no CAS
  Sponsors:   Thomas G. Brott, M.D.;   National Institute of Neurological Disorders and Stroke (NINDS)
  Recruiting
• Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

  NCT01872975

  Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
  Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
  Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

  NCT03987620

  Condition:   Candida Vulvovaginitis
  Interventions:   Drug: Ibrexafungerp;   Drug: Placebo
  Sponsors:   Scynexis, Inc.;   PPD
  Recruiting
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

  NCT03893448

  Conditions:   Pneumococcal Infections;   Pneumococcal Vaccines
  Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: RotaTeq™;   Biological: Pentacel™;   Biological: RECOMBIVAX HB™;   Biological: VAQTA™;   Biological: M-M-R™;   Biological: VARIVAX™;   Biological: HIBERIX™
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

  NCT03847896

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Budesonide metered-dose inhaler 160 µg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg;   Combination Product: Placebo metered-dose inhaler
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Intervention:   Drug: Rucaparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

  NCT03769090

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting
• Product Surveillance Registry

  NCT01524276

  Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
  Intervention:  
  Sponsor:   Medtronic
  Recruiting
• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

  NCT00271180

  Conditions:   Arrhythmia;   Bradycardia;   Heart Failure;   Sinus Tachycardia
  Intervention:   Device: Device
  Sponsor:   Medtronic
  Recruiting